Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sutro BiopharmaSTRO -4.16%45 Net Cash per Share is $-8.05 as of Jun. 2026. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 785 Biotechnology companies, Sutro Biopharma ranks worse than 127388.41% on this metric.
The historical rank and industry rank for Sutro Biopharma's Net Cash per Share or its related term are showing as below:
During the past 10 years, the highest Price-to-Net-Cash Ratio of Sutro Biopharma was 44.84. The lowest was 1.55. And the median was 3.38.
STRO's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.19 * Ranked among companies with meaningful Price-to-Net-Cash only.
Sutro Biopharma (NAS:STRO) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Sutro Biopharma Net Cash per Share Related Terms
Sutro Biopharma Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STRO vs AVIR, IPSC, CCCC: Net Cash per Share Comparison
For the Biotechnology subindustry, Sutro Biopharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Sutro Biopharma's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (STRO) has a Net Cash per Share of $-8.05 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sutro Biopharma and its competitors. Over the past decade, Sutro Biopharma's Net Cash per Share has ranged from 1.55 to 44.84. According to the industry distribution chart, Sutro Biopharma ranks #999999 out of 785 companies in the Biotechnology industry.
Is Sutro Biopharma's Net Cash per Share too high?
Sutro Biopharma's current Net Cash per Share is $-8.05. Over the past 10 years, this metric has ranged from a low of 1.55 to a high of 44.84. Based on the distribution chart, Sutro Biopharma ranks #999999 out of 785 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Net Cash per Share compare to AVIR and IPSC?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #999999 out of 785 companies for Net Cash per Share. This places Sutro Biopharma in the lower half of its industry. The industry median Net Cash per Share is 5.19. Historically, Sutro Biopharma's own Net Cash per Share has ranged from 1.55 to 44.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.19, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sutro Biopharma and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Net Cash per Share is $-8.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current Net Cash per Share is $-8.05. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Net Cash per Share is $-8.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STRO) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for STRO:
Net Cash per Share: $-8.05
GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STRO
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STRO has been successfully added to your 
